INCY
Incyte Hits Stride in 2024 Q4, Eyes $1B Revenue Boost from New Product Launches
Incyte, a leading biopharmaceutical company, ended 2024 on a high note, delivering another strong year with total revenues growing 15% to reach $4.2 billion. The company's consistent performance in the fourth quarter was driven by the continued growth of Jakafi, as well as strong momentum from its